Xtant Medical enters $9.75M private placement; Vizirgianakis to become Chairman

Xtant Medical Holdings, Inc.

Gross proceeds ~$9.75M from 20.3M shares and 5.1M warrants at $0.48/unit; first close ~$6.75M.
First closing expected ~Aug 26, 2022; second close ~Oct 2022 after 20-day stockholder notice period.
Stavros Vizirgianakis to become Non-Executive Chairman upon first closing, replacing Jeffrey Peters.
Warrants exercisable at $0.48/share for five years; 3-month lock-up for most investors, 12-month for lead.
Net proceeds to be used for working capital and general corporate purposes.

item 1.01 item 3.02 item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Jeffrey Peters

Chairman of the Board

XTNT · Xtant Medical Holdings, Inc.

Successor: Stavros Vizirgianakis
Filed: August 24, 2022, 7:59 PM ET

to replace Jeffrey Peters, who is currently serving as Chairman of the Board and intends not to stand for re-election at the Company's next annual meeting of stockholders

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.9

Jeffrey Peters changed role as Chairman of the Board at Xtant Medical Holdings, Inc..

Action: replaced as Chairman
Role: Chairman of the Board

Exact text from the filing

to replace Jeffrey Peters, who is currently serving as Chairman of the Board and intends not to stand for re-election at the Company's next annual meeting of stockholders

View on SEC.gov

Xtant Medical Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-023900

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.